Here, we demonstrate that the activation of ERβ in chemotherapy-resistant triple-negative breast cancer cell lines elicits equivalent or superior inhibitory effects compared to chemotherapy-sensitive counterparts. The gene discussed is ESR2; the disease is triple-negative breast carcinoma.